Present status and perspectives in the treatment of hormone-refractory prostate cancer

Nicola Silvestris, Bernardo Leone, Gianmauro Numico, Vito Lorusso, Mario De Lena

Research output: Contribution to journalArticlepeer-review


The cornerstone in the treatment of de novo or recurrent metastatic prostate cancer is androgen deprivation. Unfortunately, nearly all patients will develop androgen-independent ('hormone-refractory') disease with progressive clinical deterioration and ultimately death. Chemotherapy has been shown to palliate symptoms of hormone-refractory disease but not to improve survival. Recently, two large phase III trials have demonstrated an overall survival advantage for patients treated with docetaxel-based regimens as compared to the best standard of care. Indeed, investigations into the pathophysiology of this malignancy, novel biological agents, skeletal protectants and radiopharmaceuticals are expanding the clinician's armamentarium and improving the patient's outcome.

Original languageEnglish
Pages (from-to)273-282
Number of pages10
Issue number4
Publication statusPublished - Nov 2005


  • Androgen deprivation
  • Chemotherapy
  • Hormone-refractory cancer
  • Prostate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Present status and perspectives in the treatment of hormone-refractory prostate cancer'. Together they form a unique fingerprint.

Cite this